Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2026)

Castle Biosciences has reported Cash & Equivalents for 9 years, with the latest figure at $62.1 million in Q2 2026.

• Quarterly Cash & Equivalents fell 24.46% year-over-year to $62.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $62.1 million (down 24.46% YoY) and the FY2025 annual result came in at $116.7 million, down 2.49% from the prior year.
• Cash & Equivalents eased to $62.1 million in Q2 2026 per CSTL's latest filing, from $63.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $309.0 million in Q1 2022 and troughed at $62.1 million in Q2 2026.
• A 5-year average of $118.0 million and a median of $95.4 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 64.89% in 2023, then grew 21.11% in 2024.
• Over 5 years, Cash & Equivalents stood at $122.9 million in 2022, then declined by 19.61% to $98.8 million in 2023, then climbed by 21.11% to $119.7 million in 2024, then slipped by 2.49% to $116.7 million in 2025, then tumbled by 46.79% to $62.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $62.1 million, $63.8 million, and $116.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.